Live Breaking News & Updates on முதுமறதி அறிக்கை

Stay updated with breaking news from முதுமறதி அறிக்கை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Functional Neuromodulation Announces Breakthrough Device Designation from the U.S. FDA for Deep Brain Stimulation for Alzheimer's Disease


Share this article
Share this article
MINNEAPOLIS, Jan. 6, 2021 /PRNewswire/  Functional Neuromodulation announced today that it has received Breakthrough Device designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) for the Vercise™ Deep Brain Stimulation (DBS) Systems, developed and manufactured by Boston Scientific Corporation, in the treatment of patients 65 years and older with mild probable Alzheimer s disease. The Breakthrough Device designation will provide priority review regarding device development and assessment to help provide patients and healthcare providers gain timely access to medical devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. ....

United States , Baden Wuberg , Sachsen Anhalt , City Of , United Kingdom , Constantine Lyketsos , Andres Lozano , Los Angeles , Robyn Moxon , Todd Langevin , Johns Hopkins Bayview Medical Center , Boston Scientific , Neuromodulation Ltd , University Of Toronto , Alzheimer Disease International , European Union , Foundation Medical Partners , Breakthrough Device Designation , Functional Neuromodulation , Wake Forest , Boston Scientific Vercise , Directional System , Genesys Capital , Alzheimer Report , ஒன்றுபட்டது மாநிலங்களில் , சாச்சேன் அன்ஹால்ட் ,